Azurity Pharmaceuticals Launches BRYNOVIN™: The First Oral Liquid Sitagliptin for Type 2 Diabetes Management Azurity Pharmaceuticals unveils BRYNOVIN™, the first-ever oral liquid sitagliptin, enhancing treatment options for adults with type 2 diabetes.

Azurity Pharmaceuticals Launches BRYNOVIN™: The First Oral Liquid Sitagliptin for Type 2 Diabetes Management #United_States #Azurity_Pharmaceuticals #Woburn #BRYNOVIN #Sitagliptin